FHTX

In Q1 2026, Foghorn Therapeutics reported a net loss of $19.9 million and decreased collaboration revenue. The company's Q1 2026 revenue missed estimates. As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $183.6 million, partly due to a direct equity and warrant financing in January 2026. The company reported Q4 2025 earnings on March 11, 2026, missing analysts' expectations. Foghorn Therapeutics presented new preclinical data at the 2026 AACR Annual Meeting and participated in several healthcare conferences. As of April 30, 2026, the company had an average recommendation of "Moderate Buy" with an average one-year price target of $11.1250.